Sec Form 4 Filing - Fong Ivan K @ Medtronic plc - 2022-02-01

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Fong Ivan K
2. Issuer Name and Ticker or Trading Symbol
Medtronic plc [ MDT]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
EVP GENERAL COUNSEL & SECR
(Last) (First) (Middle)
710 MEDTRONIC PARKWAY LC300
3. Date of Earliest Transaction (MM/DD/YY)
02/01/2022
(Street)
MINNEAPOLIS, MN55432
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 02/01/2022 A( 1 ) 6,237 A $ 0 6,237 D
Ordinary Shares 02/01/2022 A( 2 ) 24,134 A $ 0 30,371 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $ 103.59 02/01/2022 A 50,476 08/02/2022( 3 ) 08/02/2031 Ordinary Shares 50,476 $ 103.59 50,476 D
Performance Share Units ( 4 ) 02/01/2022 A 15,591( 5 ) ( 6 ) ( 6 ) Performance Share Units 15,591 $ 0 15,591 D
Stock Option (Right to Buy) $ 103.59 02/01/2022 A 145,852 02/01/2023( 7 ) 02/01/2032 Ordinary Shares 145,852 $ 103.59 145,852 D
Performance Share Units ( 4 ) 02/01/2022 A 21,238( 8 ) ( 6 ) ( 6 ) Performance Share Units 21,238 $ 0 21,238 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Fong Ivan K
710 MEDTRONIC PARKWAY LC300
MINNEAPOLIS, MN55432
EVP GENERAL COUNSEL & SECR
Signatures
/s/ Thomas L. Osteraas, attorney-in-fact 02/03/2022
Signature of Reporting Person Date
Explanation of Responses:
( 1 )The restrictions on these restricted stock units shall lapse 100% on August 2, 2024.
( 2 )The restrictions on these restricted stock units shall vest 50% on December 10, 2022, 25% on December 10, 2023 and 25% on December 10, 2024.
( 3 )These options become exercisable at the rate of 25% of the shares granted per year beginning on the date noted.
( 4 )Each performance share unit represents a contingent right to receive one share of Medtronic common stock.
( 5 )The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 15,591 shares will be issued. The actual number of shares to be issued could range from a low of 3,118 at minimum performance to a high of 31,182 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares.
( 6 )Vests on August 2, 2024.
( 7 )These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant.
( 8 )The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 21,238 shares will be issued. The actual number of shares to be issued could range from a low of 4,248 at minimum performance to a high of 42,476 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.